Literature DB >> 1728075

Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors.

O Søreide1, T Berstad, A Bakka, E Schrumpf, L E Hanssen, V Engh, A Bergan, A Flatmark.   

Abstract

Seventy-five patients with advanced abdominal carcinoid tumors (65 midgut, 10 others) have been examined retrospectively to evaluate the role of surgical treatment as a principle, irrespective of stage of disease. Eighteen of 52 patients (35%) exhibited the carcinoid syndrome. Two or more primaries were found in 39% of patients with midgut lesion, 81% of these patients had regional metastases, 5% of these patients had distant lymph node metastases, and 74% of the patients had liver secondaries. All patients underwent operation, an additional 34% of the patients had a further reoperation, 9% of the patients had a second reoperation, 3% of the patients had a third reoperation, and one patient (2%) had a fourth reoperation. Intraoperative debulking (liver excluded) was performed in 33% of the patients, and 48% of the patients had treatment (resection, hepatic artery ligation, embolization) directed at the liver. The postoperative mortality rate was 2% after the primary operation for midgut lesions. The median survival for midgut tumors was 92 months, compared to 40 months for other lesions (not significant). A significantly higher survival rate was revealed for those patients with midgut lesion who were undergoing intraabdominal debulking procedures (liver excluded); median survival was 139 months versus 69 months without debulking. For those patients with liver metastases, median survival after intervention was 216 months and 48 months without such treatment (p less than 0.001). It is concluded that resection of intraabdominal carcinoid tumor masses can be performed in a high proportion of patients. Despite the retrospective, uncontrolled nature of this study, the difference in survival probabilities in favor of aggressive surgical therapy is so marked that it is not unreasonable to conclude that surgery has played a role in prolonging life in these patients.

Entities:  

Mesh:

Year:  1992        PMID: 1728075

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  31 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 2.  Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature.

Authors:  Wojciech C Blonski; K Rajender Reddy; Abraham Shaked; Evan Siegelman; David C Metz
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.

Authors:  Gregory Kaltsas; Martyn Caplin; Philippa Davies; Diego Ferone; Rocio Garcia-Carbonero; Simona Grozinsky-Glasberg; Dieter Hörsch; Eva Tiensuu Janson; Reza Kianmanesh; Beata Kos-Kudla; Marianne Pavel; Anja Rinke; Massimo Falconi; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2017-03-02       Impact factor: 4.914

4.  Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.

Authors:  Diamantis I Tsilimigras; J Madison Hyer; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Joal D Beane; Mary Dillhoff; Allan Tsung; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2021-01-05       Impact factor: 3.452

5.  Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Ioannis D Kostakis; Demetrios Moris; Dimitrios Schizas; Jordan M Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

Review 6.  Liver transplantation for malignancies.

Authors:  Bijan Eghtesad; Federico Aucejo
Journal:  J Gastrointest Cancer       Date:  2014-09

7.  Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours.

Authors:  Ashley Kieran Clift; Omar Faiz; Adil Al-Nahhas; Andreas Bockisch; Marc Olaf Liedke; Erik Schloericke; Harpreet Wasan; John Martin; Paul Ziprin; Krishna Moorthy; Andrea Frilling
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

Review 8.  [Indications and operative procedures for neuroendocrine liver metastases].

Authors:  T J Musholt; H Lang
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

9.  Multifocality in Small Bowel Neuroendocrine Tumors.

Authors:  Alexandra Gangi; Emily Siegel; Galinos Barmparas; Simon Lo; Laith H Jamil; Andrew Hendifar; Nicholas N Nissen; Edward M Wolin; Farin Amersi
Journal:  J Gastrointest Surg       Date:  2017-11-08       Impact factor: 3.452

Review 10.  Liver transplantation for neuroendocrine tumour liver metastases.

Authors:  Sheung Tat Fan; Yves Patrice Le Treut; Vincenzo Mazzaferro; Andrew K Burroughs; Michael Olausson; Stefan Breitenstein; Andrea Frilling
Journal:  HPB (Oxford)       Date:  2014-07-03       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.